Trial Profile
Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD33 CAR NK92 cell therapy PersonGen Biomedicine (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 07 Nov 2016 New trial record